Lexicon Pharmaceuticals, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-50.3M | $-200.4M | $-177.1M | $-101.9M | $-87.8M | $-58.6M | $130.1M | $-120.5M |
| Depreciation & Amortization | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $2.9M | $3.7M | $3.7M |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | $1.8M |
| Stock-Based Compensation | $12.5M | $13.5M | $14.3M | $11.5M | $10.6M | $13.3M | $14.2M | $11.7M |
| Net Cash from Operating Activities | $-67.9M | $-178.8M | $-161.9M | $-88.9M | $-87.0M | $-143.0M | $113.8M | $-148.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $1.0M | $470.0K | $1.3M | $1.2M | $87.0K | $70.0K | $95.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $113.0M | $-15.4M | $-49.9M | $-71.1M | $2.1M | $380.8M | $-155.9M | $169.6M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | $1.7M | $824.0K | $864.0K | $2.7M | $1.0M | $941.0K | $972.0K |
| Net Cash from Financing Activities | $-48.5M | $238.3M | $188.0M | $142.2M | $22.7M | $-147.6M | $-2.2M | $-2.2M |
| Net Change in Cash | $-3.3M | $44.2M | $-23.9M | $-17.7M | $-62.2M | $90.2M | $-44.3M | $18.7M |
| Free Cash Flow | $-67.9M | $-179.8M | $-162.4M | $-90.2M | $-88.2M | $-143.1M | $113.7M | $-148.7M |